Price Size
$280 100ul
$350 200ul

Same day delivery

Contact distributor
  • Product Name
    Phospho-GSK3 beta (Ser9) Antibody
  • Catalog No.
    AF2016
  • Source
    Rabbit
  • Application
    WB,IHC,IF/ICC,IP,ELISA
  • Reactivity:
    Human, Mouse, Rat
  • Prediction:
    Pig(100%), Zebrafish(100%), Rabbit(100%), Dog(100%), Xenopus(100%)
  • UniProt
  • Mol.Wt.
    46kDa
  • Concentration
    1mg/ml
  • Browse similar products>>

Product Information

Alternative Names:Expand▼

Glycogen Synthase Kinase 3 Beta; Glycogen synthase kinase-3 beta; GSK 3 beta; GSK-3 beta; GSK3B; GSK3B_HUMAN; GSK3beta isoform; Serine/threonine-protein kinase GSK3B;

Applications:

WB 1:500-1:2000, IHC 1:50-1:500, IF 1:100-1:500, IP 1:100-1:500, ELISA(peptide) 1:20000-1:40000

Reactivity:

Human, Mouse, Rat

Predicted Reactivity:

Pig(100%), Zebrafish(100%), Rabbit(100%), Dog(100%), Xenopus(100%)

Source:

Rabbit

Clonality:

Polyclonal

Purification:

The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.

Specificity:

Phospho-GSK3 beta (Ser9) Antibody detects endogenous levels of GSK3 beta only when phosphorylated at Serine 9.

Format:

Liquid

Concentration:

1mg/ml

Storage Condition and Buffer:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt.

Immunogen Information

Immunogen:

A synthesized peptide derived from human GSK3 beta around the phosphorylation site of Ser9.

Uniprot:



>>Visit The Human Protein Atlas

Gene id:

Molecular Weight:

Observed Mol.Wt.: 46kDa.
Predicted Mol.Wt.: 47kDa.

Subcellular Location:

Cytoplasm. Nucleus. Cell membrane. The phosphorylated form shows localization to cytoplasm and cell membrane. The MEMO1-RHOA-DIAPH1 signaling pathway controls localization of the phosophorylated form to the cell membrane.

Tissue Specificity:

Expressed in testis, thymus, prostate and ovary and weakly expressed in lung, brain and kidney. Colocalizes with EIF2AK2/PKR and TAU in the Alzheimer disease (AD) brain.

Description:

GSK3B a proline-directed protein kinase of the GSK family. Phosphorylates and inactivates glycogen synthase. Participates in the Wnt signaling pathway. Involved in energy metabolism, neuronal cell development, and body pattern formation .

Sequence:
        10         20         30         40         50
MSGRPRTTSF AESCKPVQQP SAFGSMKVSR DKDGSKVTTV VATPGQGPDR
60 70 80 90 100
PQEVSYTDTK VIGNGSFGVV YQAKLCDSGE LVAIKKVLQD KRFKNRELQI
110 120 130 140 150
MRKLDHCNIV RLRYFFYSSG EKKDEVYLNL VLDYVPETVY RVARHYSRAK
160 170 180 190 200
QTLPVIYVKL YMYQLFRSLA YIHSFGICHR DIKPQNLLLD PDTAVLKLCD
210 220 230 240 250
FGSAKQLVRG EPNVSYICSR YYRAPELIFG ATDYTSSIDV WSAGCVLAEL
260 270 280 290 300
LLGQPIFPGD SGVDQLVEII KVLGTPTREQ IREMNPNYTE FKFPQIKAHP
310 320 330 340 350
WTKVFRPRTP PEAIALCSRL LEYTPTARLT PLEACAHSFF DELRDPNVKL
360 370 380 390 400
PNGRDTPALF NFTTQELSSN PPLATILIPP HARIQAAAST PTNATAASDA
410 420
NTGDRGQTNN AASASASNST

Background

Function:

Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis. May also mediate the development of insulin resistance by regulating activation of transcription factors. Regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. In Wnt signaling, GSK3B forms a multimeric complex with APC, AXIN1 and CTNNB1/beta-catenin and phosphorylates the N-terminus of CTNNB1 leading to its degradation mediated by ubiquitin/proteasomes. Phosphorylates JUN at sites proximal to its DNA-binding domain, thereby reducing its affinity for DNA. Phosphorylates NFATC1/NFATC on conserved serine residues promoting NFATC1/NFATC nuclear export, shutting off NFATC1/NFATC gene regulation, and thereby opposing the action of calcineurin. Phosphorylates MAPT/TAU on 'Thr-548', decreasing significantly MAPT/TAU ability to bind and stabilize microtubules. MAPT/TAU is the principal component of neurofibrillary tangles in Alzheimer disease. Plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. Phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. Probably regulates NF-kappa-B (NFKB1) at the transcriptional level and is required for the NF-kappa-B-mediated anti-apoptotic response to TNF-alpha (TNF/TNFA). Negatively regulates replication in pancreatic beta-cells, resulting in apoptosis, loss of beta-cells and diabetes. Through phosphorylation of the anti-apoptotic protein MCL1, may control cell apoptosis in response to growth factors deprivation. Phosphorylates MUC1 in breast cancer cells, decreasing the interaction of MUC1 with CTNNB1/beta-catenin. Is necessary for the establishment of neuronal polarity and axon outgrowth. Phosphorylates MARK2, leading to inhibit its activity. Phosphorylates SIK1 at 'Thr-182', leading to sustain its activity. Phosphorylates ZC3HAV1 which enhances its antiviral activity. Phosphorylates SNAI1, leading to its BTRC-triggered ubiquitination and proteasomal degradation. Phosphorylates SFPQ at 'Thr-687' upon T-cell activation. Phosphorylates NR1D1 st 'Ser-55' and 'Ser-59' and stabilizes it by protecting it from proteasomal degradation. Regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2. Phosphorylates CLOCK AT 'Ser-427' and targets it for proteasomal degradation. Phosphorylates ARNTL/BMAL1 at 'Ser-17' and 'Ser-21' and primes it for ubiquitination and proteasomal degradation. Phosphorylates OGT at 'Ser-3' or 'Ser-4' which positively regulates its activity. Phosphorylates MYCN in neuroblastoma cells which may promote its degradation (PubMed:24391509).

Post-translational Modifications:

Phosphorylated by AKT1 and ILK1. Upon insulin-mediated signaling, the activated PKB/AKT1 protein kinase phosphorylates and desactivates GSK3B, resulting in the dephosphorylation and activation of GYS1. Activated by phosphorylation at Tyr-216 (PubMed:25169422). Inactivated by phosphorylation at Ser-9 (Probable).Mono-ADP-ribosylation by PARP10 negatively regulates kinase activity.

Subcellular Location:

Plasma membrane;Nucleus;

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionGraphics by Christian Stolte

Subunit Structure:

Monomer. Interacts with ARRB2, DISC1 and ZBED3 (By similarity). Interacts with CABYR, MMP2, MUC1, NIN and PRUNE1. Interacts with AXIN1; the interaction mediates hyperphosphorylation of CTNNB1 leading to its ubiquitination and destruction. Interacts with and phosphorylates SNAI1. Interacts with DNM1L (via a C-terminal domain). Found in a complex composed of MACF1, APC, AXIN1, CTNNB1 and GSK3B (By similarity). Interacts with SGK3. Interacts with DAB2IP (via C2 domain); the interaction stimulates GSK3B kinase activation. Interacts (via C2 domain) with PPP2CA. Interacts with the CLOCK-ARNTL/BMAL1 heterodimer. Interacts with the ARNTL/BMAL1. Interacts with CTNND2 (PubMed:19706605). Interacts with NCYM (PubMed:24391509). The complex composed, at least, of APC, CTNNB1 and GSK3B interacts with JPT1; the interaction requires the inactive form of GSK3B (phosphorylated at 'Ser-9') (PubMed:25169422). Forms a complex composed of PRKAR2A or PRKAR2B, GSK3B and GSKIP through GSKIP interaction; facilitates PKA-induced phosphorylation and regulates GSK3B activity (PubMed:27484798, PubMed:20007971, PubMed:25920809). Interacts with GSK3B; induces GSK3B-mediated phosphorylation of GSKIP (PubMed:16981698).

Similarity:

Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. GSK-3 subfamily.

Research Fields

Research Fields:

· Cellular Processes > Cell growth and death > Cell cycle.(View pathway)
· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.(View pathway)
· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells.(View pathway)
· Environmental Information Processing > Signal transduction > Hippo signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > ErbB signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > Wnt signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > mTOR signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > Hedgehog signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.(View pathway)
· Human Diseases > Cancers: Specific types > Basal cell carcinoma.(View pathway)
· Human Diseases > Cancers: Overview > Pathways in cancer.(View pathway)
· Human Diseases > Cancers: Specific types > Gastric cancer.(View pathway)
· Human Diseases > Cancers: Specific types > Colorectal cancer.(View pathway)
· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.(View pathway)
· Human Diseases > Cancers: Specific types > Endometrial cancer.(View pathway)
· Human Diseases > Cancers: Specific types > Breast cancer.(View pathway)
· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.
· Human Diseases > Infectious diseases: Viral > Hepatitis C.
· Human Diseases > Infectious diseases: Viral > Measles.
· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.
· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.
· Human Diseases > Infectious diseases: Viral > Influenza A.
· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.
· Human Diseases > Infectious diseases: Viral > HTLV-I infection.
· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).
· Human Diseases > Neurodegenerative diseases > Alzheimer's disease.
· Human Diseases > Cancers: Specific types > Prostate cancer.(View pathway)
· Organismal Systems > Immune system > IL-17 signaling pathway.(View pathway)
· Organismal Systems > Immune system > T cell receptor signaling pathway.(View pathway)
· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway.(View pathway)
· Organismal Systems > Endocrine system > Insulin signaling pathway.(View pathway)
· Organismal Systems > Endocrine system > Prolactin signaling pathway.(View pathway)
· Organismal Systems > Nervous system > Neurotrophin signaling pathway.(View pathway)
· Organismal Systems > Nervous system > Dopaminergic synapse.
· Organismal Systems > Development > Axon guidance.(View pathway)
· Organismal Systems > Endocrine system > Melanogenesis.
· Organismal Systems > Immune system > Chemokine signaling pathway.(View pathway)
· Organismal Systems > Immune system > B cell receptor signaling pathway.(View pathway)

Western blot analysis of extracts from various samples, using Phospho-GSK3 beta (Ser9) Antibody. Lane 1: Mouse brain lysates; Lane 2: Rat liver lysates; Lane 3: Rat kidney lysates; Lane 4: Rat kidney lysates treated with blocking peptide;
Western blot analysis of extracts from various samples, using Phospho-GSK3 beta (Ser9) Antibody. Lane 1: Mouse brain lysates; Lane 2: Mouse muscle lysates; Lane 3: Mouse muscle lysates treated with blocking peptide;
AF2016 at 1/100 staining rat ovarian tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF2016 at 1/100 staining rat gastric tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF2016 at 1/100 staining rat uterine tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF2016 at 1/100 staining human glioma tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF2016 at 1/100 staining human gastric tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF2016 at 1/100 staining human pancreatic tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF2016 at 1/100 staining mouse brain tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF2016 at 1/100 staining mouse kidney tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF2016 at 1/100 staining mouse gastric tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
AF2016 staining HuvEc by IF/ICC. The sample were fixed with PFA and permeabilized in 0.1% Triton X-100,then blocked in 10% serum for 45 minutes at 25°C. The primary antibody was diluted at 1/200 and incubated with the sample for 1 hour at 37°C. An Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) Ab, diluted at 1/600, was used as the secondary antibody.
AF2016 staining lovo cells by ICC/IF. Cells were fixed with PFA and permeabilized in 0.1% saponin prior to blocking in 10% serum for 45 minutes at 37°C. The primary antibody was diluted 1/400 and incubated with the sample for 1 hour at 37°C. A Alexa Fluor® 594 conjugated goat polyclonal to rabbit IgG (H+L), diluted 1/600 was used as secondary antibody.
ELISA analysis of AF2016 showing specificity to Phospho-GSK3 beta (Ser9) peptide. Peptides concentration: 1ug/ml.
P-peptide: phospho-peptide; N-peptide: non-phospho-peptide.

Reference Citations:

1). Zheng Q et al. MicroRNA-200c impairs uterine receptivity formation by targeting FUT4 and α1,3-fucosylation. Cell Death Differ 2017 Dec;24(12):2161-2172 (PubMed: 28914881) [IF=8.086]

Application: WB    Species:human;    Sample:Not available

Figure 4 miR-200c decreases α1,3-fucosylation on CD44 and inactivates Wnt/β-catenin signaling pathway. (a, e) Western/lectin blot analysis of effect of miR-200c on α1,3- fucosylation and LeY biosynthesis in RL95-2 (a) and Ishikawa (e) cells. CBB: coomassie brilliant blue. LTL: Lotus tetragonolobus lectin. (b, f) Immunoprecipitation and western blot analysis of α 1,3-fucosylation and LeY on CD44 in RL95-2 (b) and Ishikawa (f) cells. Immunoprecipitation (IP): anti-CD44 antibody pulled down protein. Immune blot (IB): detection of α 1,3-fucosylation by LTL lectin and anti-LeY antibody. (c, g) Western blot analysis of CD44, LTL and LeY blocking on activation of p-GSK3β, GSK3β and β-catenin in RL95-2 (c) and Ishikawa (g) cells. (d, h) Western blot and statistical analysis of p-GSK3β, GSK3β and β-catenin in RL95-2 (d) and Ishikawa (h) cells. DKK: inhibitor of Wnt/β- catenin signal pathway. *Po0.05, **Po0.01, ***Po0.


2). Yang K et al. Ursolic Acid promotes apoptosis and mediates transcriptional suppression of CT45A2 gene expression in NSCLCs harboring EGFR T790M. Br J Pharmacol 2019 Jul 19 (PubMed: 31322286) [IF=6.583]

3). Zhang P et al. AMPK/GSK3β/β-catenin cascade-triggered overexpression of CEMIP promotes migration and invasion in anoikis-resistant prostate cancer cells by enhancing metabolic reprogramming. FASEB J 2018 Jul;32(7):3924-3935 (PubMed: 29505302) [IF=5.391]

4). Cheng XY et al. Effects of dexmedetomidine postconditioning on myocardial ischemia and the role of the PI3K/Akt-dependent signaling pathway in reperfusion injury. Mol Med Rep 2016 Jul;14(1):797-803 (PubMed: 27221008)

Application: WB    Species:rat;    Sample:Not available


5). Yao R et al. Lithium chloride inhibits cell survival, overcomes drug resistance, and triggers apoptosis in multiple myeloma via activation of the Wnt/β-catenin pathway. Am J Transl Res 2018 Aug 15;10(8):2610-2618 (PubMed: 30210697)

6). Guo LT et al. Baicalin ameliorates neuroinflammation-induced depressive-like behavior through inhibition of toll-like receptor 4 expression via the PI3K/AKT/FoxO1 pathway. J Neuroinflammation 2019 May 8;16(1):95 (PubMed: 31068207)

7). Wei A et al. ST6Gal-I overexpression facilitates prostate cancer progression via the PI3K/Akt/GSK-3β/β-catenin signaling pathway. Oncotarget 2016 Oct 4;7(40):65374-65388 (PubMed: 27588482)

Application: WB    Species:human;    Sample:Not available

(D and E) PCa cells were pretreated with wortmannin and Akt RNAi, and PI3K/Akt/GSK-3β/β-catenin pathway signaling molecule expression levels were analyzed by Western blotting.


8). Liu HJ et al. A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor γ with Excellent Effect on Insulin Resistance and Type 2 Diabetes. J Pharmacol Exp Ther 2015 Jun;353(3):573-81 (PubMed: 25876909)

9). Zhang YM et al. Baicalin promotes embryo adhesion and implantation by upregulating fucosyltransferase IV (FUT4) via Wnt/beta-catenin signaling pathway. FEBS Lett 2015 May 8;589(11):1225-33 (PubMed: 25896022)

Application: WB    Species:Not available;    Sample:Not available


10). Liu Y et al. Oligo-Porphyran Ameliorates Neurobehavioral Deficits in Parkinsonian Mice by Regulating the PI3K/Akt/Bcl-2 Pathway. Mar Drugs 2018 Mar 6;16(3) (PubMed: 29509717)

11). Ma Z et al. Autophagy promotes hepatic differentiation of hepatic progenitor cells by regulating the Wnt/β-catenin signaling pathway. J Mol Histol 2019 Jan 2 (PubMed: 30604254)

No comment
Total 0 records, divided into1 pages. First Prev Next Last

Submit Review

Support JPG, GIF, PNG format only
captcha
Catalog Number :

AF2016-BP

Price/Size :

$200/1mg.
Tips: For phospho antibody, we provide phospho peptide(0.5mg) and non-phospho peptide(0.5mg).

Function :

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (immunoblot) and immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or immunostaining performed with the neutralized antibody.

Format and storage :

Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.The purity is >90%,tested by HPLC and MS.Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions :

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

Xenopus
100%
Zebrafish
100%
Rabbit
100%
Pig
100%
Dog
100%
Horse
0%
Chicken
0%
Bovine
0%
Sheep
0%
High similarity Medium similarity Low similarity No similarity
P49841 as Substrate
Site PTM Type Enzyme
T7 Phosphorylation
T8 Phosphorylation
S9 Phosphorylation P05129 (PRKCG) , Q05513 (PRKCZ) , P31751 (AKT2) , Q9Y4K4 (MAP4K5) , Q9UM73 (ALK) , O14965 (AURKA) , P23443 (RPS6KB1) , Q13237 (PRKG2) , P05771 (PRKCB) , P51812 (RPS6KA3) , Q15831 (STK11) , Q9UBS0 (RPS6KB2) , P49841 (GSK3B) , P24723 (PRKCH) , P17612 (PRKACA) , O94806 (PRKD3) , Q05655 (PRKCD) , P31749 (AKT1) , P17252 (PRKCA) , Q15418 (RPS6KA1) , Q9Y243 (AKT3) , Q96BR1 (SGK3)
S13 Phosphorylation
K15 Ubiquitination
S21 Phosphorylation
S25 Phosphorylation
K27 Methylation
K27 Ubiquitination
S35 Phosphorylation
K36 Ubiquitination
T43 Phosphorylation P27361 (MAPK3) , P28482 (MAPK1)
S66 Phosphorylation
Y71 Phosphorylation
K85 Ubiquitination
K103 Ubiquitination
Y114 Phosphorylation
Y117 Phosphorylation
S147 Phosphorylation Q05513 (PRKCZ)
K183 Ubiquitination
K197 Ubiquitination
S203 Phosphorylation
K205 Acetylation
K205 Ubiquitination
S215 Phosphorylation
Y216 Phosphorylation P49841 (GSK3B) , Q02750 (MAP2K1)
S219 Phosphorylation
Y221 Phosphorylation
Y222 Phosphorylation
T275 Phosphorylation
T277 Phosphorylation
Y288 Phosphorylation
K292 Sumoylation
K292 Ubiquitination
K297 Ubiquitination
C317 S-Nitrosylation
K349 Ubiquitination
S389 Phosphorylation Q16539 (MAPK14)
T390 Phosphorylation Q16539 (MAPK14)
T392 Phosphorylation
T395 Phosphorylation
T402 Phosphorylation
S417 Phosphorylation
T420 Phosphorylation
P49841 as PTM Enzyme
Substrate Site Source
E9PAV3 (NACA) T2022 Signor
O00327 (ARNTL) S17 Signor
O00327 (ARNTL) T21 Signor
O00429 (DNM1L) S40 Calculation
O00429 (DNM1L) S44 Calculation
O00429 (DNM1L) S693 Calculation
O15169 (AXIN1) T481 neXtProt, Signor
O15169 (AXIN1) S486 neXtProt, Signor
O15169-2 (AXIN1) S614 HPRD
O15294 (OGT) S3 Calculation
O15294 (OGT) S4 Calculation
O15516 (CLOCK) S427 Calculation
O43602-2 (DCX) S327 Calculation
O43602 (DCX) S332 Signor
O43623 (SNAI2) S92 Calculation
O43623 (SNAI2) S96 Calculation
O43623 (SNAI2) S100 Calculation
O43623 (SNAI2) S104 Calculation
O60341 (KDM1A) S683 Calculation
O60346 (PHLPP1) S1359 Signor
O60346 (PHLPP1) T1363 Calculation
O60346 (PHLPP1) S1379 Calculation
O60346 (PHLPP1) S1381 Calculation
O60716-6 (CTNND1) S252 HPRD
O60716-6 (CTNND1) T310 HPRD
O75030-10 (MITF) S292 HPRD
O75030-9 (MITF) S298 Calculation
O75030-8 (MITF) S383 HPRD
O75030-9 (MITF) S397 Calculation
O75030-6 (MITF) S398 HPRD
O75030-2 (MITF) S399 HPRD
O75030-9 (MITF) S401 Calculation
O75030-9 (MITF) S405 Calculation
O75122 (CLASP2) S499 Calculation
O75122 (CLASP2) S503 Calculation
O75122 (CLASP2) S507 Calculation
O75122 (CLASP2) S533 Calculation
O75122 (CLASP2) S537 Calculation
O75581 (LRP6) S1490 Signor
O75581 (LRP6) T1572 HPRD
O75581 (LRP6) S1607 HPRD
O75925 (PIAS1) S17 Calculation
O75952-5 (CABYR) T53 HPRD
O75952-5 (CABYR) S57 HPRD
O75952-2 (CABYR) T133 HPRD
O75952-2 (CABYR) S137 HPRD
O75952 (CABYR) T151 Calculation
O75952-4 (CABYR) S155 Calculation
O95271 (TNKS) S978 Calculation
O95271 (TNKS) T982 Calculation
O95271 (TNKS) S987 Calculation
O95271 (TNKS) S991 Calculation
O95863 (SNAI1) S92 neXtProt
O95863 (SNAI1) S96 Signor
O95863 (SNAI1) S100 Signor
O95863 (SNAI1) S104 Signor
O95863 (SNAI1) S107 Signor
O95863 (SNAI1) S111 Signor
O95863 (SNAI1) S115 Signor
O95863 (SNAI1) S119 Signor
P01106 (MYC) T58 Signor
P01106-2 (MYC) T73 HPRD
P01112 (HRAS) T144 Calculation
P01112 (HRAS) T148 Calculation
P03372 (ESR1) S102 Signor
P03372 (ESR1) S104 Signor
P03372 (ESR1) S106 Signor
P03372 (ESR1) S118 Signor
P04150 (NR3C1) S404 Signor
P04637-1 (TP53) S33 HPRD, Signor
P04637 (TP53) S376 Calculation
P05067-4 (APP) T668 HPRD
P05067-8 (APP) T724 HPRD
P05067-1 (APP) T743 HPRD
P05412 (JUN) T239 Signor
P05412 (JUN) S243 Signor
P06401-2 (PGR) S390 Calculation
P08047 (SP1) S728 Calculation
P08047 (SP1) S732 Calculation
P10070 (GLI2) S820 Signor
P10070 (GLI2) S832 Signor
P10070 (GLI2) S863 Signor
P10636-8 (MAPT) S46 Calculation
P10636-8 (MAPT) T50 Calculation
P10636-2 (MAPT) T123 HPRD
P10636-6 (MAPT) S126 HPRD
P10636-6 (MAPT) S137 HPRD
P10636-2 (MAPT) S140 HPRD
P10636-2 (MAPT) S141 HPRD
P10636-2 (MAPT) S144 HPRD
P10636-6 (MAPT) T147 HPRD
P10636-2 (MAPT) S150 HPRD
P10636-8 (MAPT) T153 Calculation
P10636-6 (MAPT) T154 HPRD
P10636-2 (MAPT) T159 HPRD
P10636-2 (MAPT) T173 HPRD
P10636-8 (MAPT) T175 Calculation
P10636-8 (MAPT) T181 Calculation
P10636-8 (MAPT) S195 Calculation
P10636-8 (MAPT) S198 HPRD
P10636-8 (MAPT) S199 Calculation
P10636-8 (MAPT) S202 Calculation
P10636-6 (MAPT) S204 HPRD
P10636-8 (MAPT) T205 Calculation
P10636-8 (MAPT) S208 HPRD
P10636-8 (MAPT) S210 Calculation
P10636-8 (MAPT) T212 Calculation
P10636-8 (MAPT) S214 Calculation
P10636-8 (MAPT) T217 Calculation
P10636-8 (MAPT) T231 Calculation
P10636-8 (MAPT) S235 Calculation
P10636-8 (MAPT) S262 Calculation
P10636-2 (MAPT) S307 HPRD
P10636-2 (MAPT) S311 HPRD
P10636-2 (MAPT) S315 HPRD
P10636-2 (MAPT) S324 HPRD
P10636-6 (MAPT) S338 HPRD
P10636-6 (MAPT) S342 HPRD
P10636-6 (MAPT) S346 HPRD
P10636-8 (MAPT) S396 Signor
P10636 (MAPT) S400 Signor
P10636-8 (MAPT) S404 Calculation
P10636-8 (MAPT) S409 Calculation
P10636-8 (MAPT) S413 HPRD
P10636-8 (MAPT) S422 Calculation
P10636 (MAPT) T498 Signor
P10636 (MAPT) S512 Signor
P10636 (MAPT) S515 Signor
P10636 (MAPT) S516 Signor
P10636 (MAPT) S519 Signor
P10636 (MAPT) T522 Signor
P10636 (MAPT) T529 Signor
P10636 (MAPT) S531 Signor
P10636 (MAPT) T534 Signor
P10636 (MAPT) T548 neXtProt, Signor
P10636 (MAPT) S579 Signor
P10636 (MAPT) S713 Signor
P10636 (MAPT) S717 Signor
P10636 (MAPT) S721 Signor
P11388 (TOP2A) S1361 Calculation
P12036 (NEFH) S503 Signor
P12524 (MYCL) S38 Calculation
P12524 (MYCL) S42 Calculation
P12830-1 (CDH1) S847 HPRD
P13807 (GYS1) S641 HPRD, neXtProt, Signor
P13807 (GYS1) S645 Calculation
P13807-1 (GYS1) S649 HPRD
P13807-1 (GYS1) S653 Calculation
P15924 (DSP) S2845 Calculation
P15924 (DSP) S2849 Calculation
P15941-7 (MUC1) S227 HPRD
P15941-11 (MUC1) S236 HPRD
P15941-8 (MUC1) S245 HPRD
P15941 (MUC1) S1227 Calculation
P16220-2 (CREB1) S115 HPRD
P16220-1 (CREB1) S129 Calculation
P16401 (HIST1H1B) T11 Signor
P16471 (PRLR) S349 Calculation
P17275 (JUNB) S251 Calculation
P17275 (JUNB) T255 Calculation
P17676 (CEBPB) S223 Calculation
P17676 (CEBPB) T226 Signor
P17676 (CEBPB) S231 Signor
P19838-2 (NFKB1) S900 HPRD
P19838-2 (NFKB1) S904 HPRD
P19838-2 (NFKB1) S908 HPRD
P20393 (NR1D1) S55 Signor
P20393 (NR1D1) S59 Signor
P22670 (RFX1) S120 Calculation
P22670 (RFX1) T124 Calculation
P23246 (SFPQ) T687 Signor
P23760 (PAX3) S201 Calculation
P24385 (CCND1) T286 Signor
P24385 (CCND1) T288 Calculation
P24864 (CCNE1) S73 Calculation
P24864 (CCNE1) T77 Signor
P24864 (CCNE1) T395 Signor
P25054 (APC) S1501 Calculation
P25054 (APC) S1503 Calculation
P30279 (CCND2) T280 Signor
P30281 (CCND3) T283 Signor
P30291 (WEE1) S211 Calculation
P30304 (CDC25A) S76 Signor
P33076 (CIITA) S373 Signor
P35222 (CTNNB1) S33 Signor
P35222 (CTNNB1) S37 Signor
P35222 (CTNNB1) T41 Signor
P35612 (ADD2) S613 Calculation
P35612 (ADD2) S693 Calculation
P36956 (SREBF1) T426 Signor
P36956 (SREBF1) S430 Signor
P36956 (SREBF1) S434 Signor
P37840 (SNCA) S129 Calculation
P38936 (CDKN1A) T57 Calculation
P38936 (CDKN1A) S114 Signor
P40337 (VHL) S68 Calculation
P41236 (PPP1R2) T73 Calculation
P49715-1 (CEBPA) T226 HPRD
P49715-1 (CEBPA) T230 HPRD
P49716 (CEBPD) S167 Calculation
P49768 (PSEN1) S353 Signor
P49768 (PSEN1) S357 Signor
P49841 (GSK3B) S9 Calculation
P49841 (GSK3B) Y216 Signor
P50219 (MNX1) S77 Signor
P50219 (MNX1) S79 Signor
P50895 (BCAM) S596 Calculation
P53396-1 (ACLY) T447 HPRD
P53396-1 (ACLY) S451 HPRD
P53805-4 (RCAN1) S28 HPRD
P53805-2 (RCAN1) S108 HPRD
P53805-1 (RCAN1) S163 Calculation
P54132 (BLM) T171 Calculation
P54252 (ATXN3) S256 Calculation
P56524 (HDAC4) S298 Signor
P56524 (HDAC4) S302 Signor
P57059 (SIK1) T182 Calculation
P58012 (FOXL2) S33 Calculation
P60484 (PTEN) S362 Calculation
P60484 (PTEN) T366 Signor
P84022 (SMAD3) T66 Signor
Q00613 (HSF1) S303 Signor
Q00653 (NFKB2) S222 Calculation
Q00653 (NFKB2) S707 Calculation
Q00653 (NFKB2) S711 Calculation
Q01094 (E2F1) S403 Calculation
Q01094 (E2F1) T433 Calculation
Q01201 (RELB) S573 Calculation
Q01974 (ROR2) S864 Signor
Q02156 (PRKCE) S346 Signor
Q03060-16 (CREM) S83 HPRD
Q04206 (RELA) S468 Signor
Q04721 (NOTCH2) T2068 HPRD, Signor
Q04721 (NOTCH2) S2070 HPRD, Signor
Q04721 (NOTCH2) T2074 HPRD, Signor
Q04721 (NOTCH2) S2093 HPRD, Signor
Q07812 (BAX) S163 Signor
Q07817 (BCL2L1) S62 Calculation
Q07820-2 (MCL1) S159 Signor
Q07820-1 (MCL1) T163 HPRD
Q12778 (FOXO1) S325 HPRD
Q13131 (PRKAA1) S486 Calculation
Q13131 (PRKAA1) T490 Calculation
Q13144 (EIF2B5) S535 HPRD
Q13144 (EIF2B5) S540 HPRD, Signor
Q13144 (EIF2B5) S544 HPRD
Q13541 (EIF4EBP1) T37 Signor
Q13541 (EIF4EBP1) T46 Signor
Q13887 (KLF5) S303 Signor
Q14103-3 (HNRNPD) S83 Signor
Q14194 (CRMP1) T509 Signor
Q14194 (CRMP1) T514 Signor
Q14194 (CRMP1) S518 Signor
Q14195 (DPYSL3) T509 Calculation
Q14195 (DPYSL3) T514 Calculation
Q14195 (DPYSL3) S518 Calculation
Q14494 (NFE2L1) S379 Signor
Q14896 (MYBPC3) S133 Calculation
Q15208 (STK38) S6 Calculation
Q15208 (STK38) T7 Calculation
Q15746 (MYLK) S1776 Calculation
Q15797 (SMAD1) T202 Calculation
Q15853 (USF2) S155 Calculation
Q15853 (USF2) T230 Calculation
Q15910 (EZH2) S363 Calculation
Q15910 (EZH2) T367 Calculation
Q16236 (NFE2L2) S344 Calculation
Q16236 (NFE2L2) S347 Calculation
Q16555 (DPYSL2) T509 Calculation
Q16555-1 (DPYSL2) T514 Calculation
Q16555 (DPYSL2) S518 Calculation
Q6PGQ7 (BORA) S274 Signor
Q6PGQ7 (BORA) S278 Signor
Q6R327 (RICTOR) S1235 Calculation
Q6R327 (RICTOR) T1695 Calculation
Q7KZI7 (MARK2) S212 Calculation
Q8IZQ8 (MYOCD) S451 HPRD, Signor
Q8IZQ8-1 (MYOCD) S455 HPRD, Signor
Q8IZQ8 (MYOCD) S459 HPRD, Signor
Q8IZQ8 (MYOCD) S463 Signor
Q8IZQ8 (MYOCD) S626 HPRD, Signor
Q8IZQ8-1 (MYOCD) S630 HPRD, Signor
Q8IZQ8 (MYOCD) S634 HPRD, Signor
Q8IZQ8 (MYOCD) S638 Signor
Q8N122 (RPTOR) S722 Calculation
Q8N122 (RPTOR) S792 Calculation
Q8N122 (RPTOR) S859 Calculation
Q8N122 (RPTOR) S863 Calculation
Q8N122 (RPTOR) S877 Calculation
Q8NHW3 (MAFA) S49 Signor
Q8NHW3 (MAFA) T53 Signor
Q8NHW3 (MAFA) T57 Signor
Q8NHW3 (MAFA) S61 Signor
Q92597 (NDRG1) S342 neXtProt
Q92597 (NDRG1) S352 neXtProt
Q92597 (NDRG1) S362 neXtProt
Q92837 (FRAT1) S188 Calculation
Q92993 (KAT5) S86 Signor
Q92993 (KAT5) S90 Calculation
Q96F46 (IL17RA) T780 Calculation
Q96G01-1 (BICD1) S585 HPRD
Q96G01-4 (BICD1) T597 HPRD
Q96R06 (SPAG5) T111 Signor
Q96R06 (SPAG5) T937 Signor
Q96R06 (SPAG5) S974 Signor
Q96R06 (SPAG5) T978 Signor
Q96RR4 (CAMKK2) S129 Signor
Q96RR4 (CAMKK2) S133 Signor
Q96RR4 (CAMKK2) S137 Signor
Q99626 (CDX2) S283 Calculation
Q9BYG3 (NIFK) S230 Calculation
Q9BYG3 (NIFK) T234 Calculation
Q9H0B6 (KLC2) S608 Calculation
Q9H0Z9 (RBM38) S195 Signor
Q9HB09 (BCL2L12) S156 Signor
Q9NP62 (GCM1) S322 Calculation
Q9NQX3 (GPHN) S270 Signor
Q9NRD5 (PICK1) S342 Calculation
Q9NRD5 (PICK1) S415 Calculation
Q9NRR4 (DROSHA) S300 Calculation
Q9NRR4 (DROSHA) S302 Calculation
Q9NS23-2 (RASSF1) S175 Calculation
Q9NS23-2 (RASSF1) S178 Calculation
Q9NS23-2 (RASSF1) S179 Calculation
Q9NYF8 (BCLAF1) S531 Calculation
Q9UBN7 (HDAC6) S22 Calculation
Q9UKA4 (AKAP11) T1136 Calculation
Q9UKA4 (AKAP11) T1140 Calculation
Q9UKT5 (FBXO4) S12 Signor
Q9UMX1 (SUFU) S342 Calculation
Q9UQB3 (CTNND2) T1056 neXtProt
Q9Y6H5 (SNCAIP) S556 Signor
IMPORTANT: For western blots, incubate membrane with diluted antibody in 5% w/v milk , 1X TBS, 0.1% Tween®20 at 4°C with gentle shaking, overnight.